Literature DB >> 24374774

Tumor suppressor p53 and its gain-of-function mutants in cancer.

Juan Liu1, Cen Zhang, Zhaohui Feng.   

Abstract

Tumor suppressor p53 plays a pivotal role in tumor suppression. p53 is the most frequently mutated gene in cancer. As a transcription factor, p53 mainly exerts its role in tumor suppression through transcriptional regulation of its downstream target genes. Thus, p53 and its target genes form a complex p53 signaling pathway to regulate a wide variety of biological processes to prevent tumorigenesis. Recent studies have revealed that in addition to apoptosis, cell cycle arrest and senescence, p53's functions in the regulation of energy metabolism and anti-oxidant defense contribute significantly to its role in tumor suppression. Studies further show that many tumor-associated mutant p53 proteins not only lose tumor suppressive functions of wild-type p53, but also gain new oncogenic activities that are independent of wild-type p53, including promoting tumor cell proliferation, survival, metabolic changes, angiogenesis, and metastasis, which are defined as mutant p53 gain-of-function. The frequent loss of wild-type p53 function and the gain-of-function of mutant p53 in human tumors make p53 an extremely attractive target for cancer therapy. Different strategies and many small-molecule drugs are being developed for the p53-based tumor therapy. Here, we review the mechanisms of p53 in tumor suppression and gain-of-function mutant p53 in tumor development, as well as the recent advances in the development of the p53-based tumor therapy.

Entities:  

Keywords:  gain-of-function; mutant p53; p53; tumor suppressor; tumor therapy

Mesh:

Substances:

Year:  2013        PMID: 24374774      PMCID: PMC3932832          DOI: 10.1093/abbs/gmt144

Source DB:  PubMed          Journal:  Acta Biochim Biophys Sin (Shanghai)        ISSN: 1672-9145            Impact factor:   3.848


  112 in total

Review 1.  p53 ubiquitination: Mdm2 and beyond.

Authors:  Christopher L Brooks; Wei Gu
Journal:  Mol Cell       Date:  2006-02-03       Impact factor: 17.970

Review 2.  The p53 tumor suppressor: a master regulator of diverse cellular processes and therapeutic target in cancer.

Authors:  Marianne Farnebo; Vladimir J N Bykov; Klas G Wiman
Journal:  Biochem Biophys Res Commun       Date:  2010-05-21       Impact factor: 3.575

Review 3.  The role of TP53 in Cervical carcinogenesis.

Authors:  Massimo Tommasino; Rosita Accardi; Sandra Caldeira; Wen Dong; Ilaria Malanchi; Anouk Smet; Ingeborg Zehbe
Journal:  Hum Mutat       Date:  2003-03       Impact factor: 4.878

4.  Regulation of autophagy by cytoplasmic p53.

Authors:  Ezgi Tasdemir; M Chiara Maiuri; Lorenzo Galluzzi; Ilio Vitale; Mojgan Djavaheri-Mergny; Marcello D'Amelio; Alfredo Criollo; Eugenia Morselli; Changlian Zhu; Francis Harper; Ulf Nannmark; Chrysanthi Samara; Paolo Pinton; José Miguel Vicencio; Rosa Carnuccio; Ute M Moll; Frank Madeo; Patrizia Paterlini-Brechot; Rosario Rizzuto; Gyorgy Szabadkai; Gérard Pierron; Klas Blomgren; Nektarios Tavernarakis; Patrice Codogno; Francesco Cecconi; Guido Kroemer
Journal:  Nat Cell Biol       Date:  2008-05-04       Impact factor: 28.824

5.  Specific binding of MAR/SAR DNA-elements by mutant p53.

Authors:  B F Müller; D Paulsen; W Deppert
Journal:  Oncogene       Date:  1996-05-02       Impact factor: 9.867

6.  Modulation of microRNA processing by p53.

Authors:  Hiroshi I Suzuki; Kaoru Yamagata; Koichi Sugimoto; Takashi Iwamoto; Shigeaki Kato; Kohei Miyazono
Journal:  Nature       Date:  2009-07-23       Impact factor: 49.962

7.  Gain of function mutations in p53.

Authors:  D Dittmer; S Pati; G Zambetti; S Chu; A K Teresky; M Moore; C Finlay; A J Levine
Journal:  Nat Genet       Date:  1993-05       Impact factor: 38.330

8.  Mutation of RRM2B, encoding p53-controlled ribonucleotide reductase (p53R2), causes severe mitochondrial DNA depletion.

Authors:  Alice Bourdon; Limor Minai; Valérie Serre; Jean-Philippe Jais; Emmanuelle Sarzi; Sophie Aubert; Dominique Chrétien; Pascale de Lonlay; Véronique Paquis-Flucklinger; Hirofumi Arakawa; Yusuke Nakamura; Arnold Munnich; Agnès Rötig
Journal:  Nat Genet       Date:  2007-05-07       Impact factor: 38.330

9.  Mutant p53 drives invasion in breast tumors through up-regulation of miR-155.

Authors:  P M Neilsen; J E Noll; S Mattiske; C P Bracken; P A Gregory; R B Schulz; S P Lim; R Kumar; R J Suetani; G J Goodall; D F Callen
Journal:  Oncogene       Date:  2012-07-16       Impact factor: 9.867

10.  Mutant p53 gain-of-function induces epithelial-mesenchymal transition through modulation of the miR-130b-ZEB1 axis.

Authors:  P Dong; M Karaayvaz; N Jia; M Kaneuchi; J Hamada; H Watari; S Sudo; J Ju; N Sakuragi
Journal:  Oncogene       Date:  2012-07-30       Impact factor: 9.867

View more
  48 in total

1.  P53 mutations and cancer: a tight linkage.

Authors:  Francesco Perri; Salvatore Pisconti; Giuseppina Della Vittoria Scarpati
Journal:  Ann Transl Med       Date:  2016-12

Review 2.  Development of cancer-initiating cells and immortalized cells with genomic instability.

Authors:  Ken-Ichi Yoshioka; Yuko Atsumi; Hitoshi Nakagama; Hirobumi Teraoka
Journal:  World J Stem Cells       Date:  2015-03-26       Impact factor: 5.326

Review 3.  Integrative analysis of aberrant Wnt signaling in hepatitis B virus-related hepatocellular carcinoma.

Authors:  Shan-Long Ding; Zi-Wei Yang; Jie Wang; Xiao-Lei Zhang; Xiang-Mei Chen; Feng-Min Lu
Journal:  World J Gastroenterol       Date:  2015-05-28       Impact factor: 5.742

Review 4.  Diagnostic molecular techniques in haematology: recent advances.

Authors:  Aikaterini Koutsi; Elisavet-Christina Vervesou
Journal:  Ann Transl Med       Date:  2018-06

5.  Gene expression profile comparison between colorectal cancer and adjacent normal tissues.

Authors:  Qian Yang; Maohui Feng; Xiang Ma; Huachi Li; Wei Xie
Journal:  Oncol Lett       Date:  2017-09-08       Impact factor: 2.967

6.  TP53 Arg72Pro polymorphism is associated with increased overall survival but not response to therapy in Portuguese/Caucasian patients with advanced cervical cancer.

Authors:  Ana Coelho; Augusto Nogueira; Sílvia Soares; Joana Assis; Deolinda Pereira; Isabel Bravo; Raquel Catarino; Rui Medeiros
Journal:  Oncol Lett       Date:  2018-03-26       Impact factor: 2.967

7.  Association Between Genetic Variant in the Promoter of Pri-miR-34b/c and Risk of Glioma.

Authors:  Jinghui Li; Xiaoyu Liu; Yu Qiao; Renli Qi; Shunjin Liu; Jing Guo; Yang Gui; Juanjuan Li; Hualin Yu
Journal:  Front Oncol       Date:  2018-09-26       Impact factor: 6.244

Review 8.  Hereditary and Sporadic Pancreatic Ductal Adenocarcinoma: Current Update on Genetics and Imaging.

Authors:  Ajaykumar C Morani; Abdelrahman K Hanafy; Nisha S Ramani; Venkata S Katabathina; Sireesha Yedururi; Anil K Dasyam; Srinivasa R Prasad
Journal:  Radiol Imaging Cancer       Date:  2020-03-13

9.  Advances in the mechanisms of action of cancer-targeting oncolytic viruses.

Authors:  Cun-Zhi Lin; Gui-Ling Xiang; Xin-Hong Zhu; Lu-Lu Xiu; Jia-Xing Sun; Xiao-Yuan Zhang
Journal:  Oncol Lett       Date:  2018-01-19       Impact factor: 2.967

10.  Glioblastoma multiforme-derived extracellular vesicles drive normal astrocytes towards a tumour-enhancing phenotype.

Authors:  Soliman Oushy; Justin E Hellwinkel; Mary Wang; Ger J Nguyen; Dicle Gunaydin; Tessa A Harland; Thomas J Anchordoquy; Michael W Graner
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2018-01-05       Impact factor: 6.237

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.